Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Transformed Non-Hodgkin Lymphoma: early-phase trial registry
3 of 7 indexed Recurrent Transformed Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Recurrent Transformed Non-Hodgkin Lymphoma: 7 US clinical trials tracked, 3 recruiting.
Recurrent Transformed Non-Hodgkin Lymphoma is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-transformed-non-hodgkin-lymphoma
OPEN 3 | RECR 43% | LATE 0 | EARLY 7 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)
Recurrent Transformed Non-Hodgkin Lymphoma lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Transformed Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Transformed Non-Hodgkin Lymphoma is recruiting below its size-band peers.
3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Transformed Non-Hodgkin Lymphoma research.
City of Hope Medical Center accounts for 2 of 7 trials (28.6%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Transformed Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 7 trials that report a genuine target (sentinel values excluded). 7 of those (100%) plan for fewer than 100 participants.
-
Recurrent Transformed Non-Hodgkin Lymphoma research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Yazeed Sawalha
NCT06536049
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Aseel Alsouqi
NCT05873712
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT05432635
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
NCT03150329
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
NCT05627245
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United
NCT02628405
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
NCT03321643
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Transformed Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Transformed Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Transformed Non-Hodgkin Lymphoma page
7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Recurrent Transformed Non-Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Recurrent Transformed Non-Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Transformed Non-Hodgkin Lymphoma condition card totals 7 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.